SCHEMBL14854360

SCHEMBL14854360

O=C1NCCc2cc(O)c(O)c(Cl)c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 9/20 0.42
▸ PARP1 P09874 7/20 0.42
▸ F7 P08709 1/20 0.42
▸ F3 P13726 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ ADCY6 O43306 1/20 0.37
▸ ADCY3 O60266 1/20 0.37
▸ ADCY9 O60503 1/20 0.37
▸ ADCY5 O95622 1/20 0.37
▸ ADCY8 P40145 1/20 0.37
▸ ADCY7 P51828 1/20 0.37
▸ ADCY2 Q08462 1/20 0.37
▸ ADCY1 Q08828 1/20 0.37
▸ ADCY4 Q8NFM4 1/20 0.37
▸ PARP11 Q9NR21 4/20 0.36
▸ DRD2 P14416 1/20 0.36
▸ DRD4 P21917 1/20 0.36
▸ PDPK1 O15530 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15814960 0.87 PARP10 (0.41) PARP10PARP1F7F3ACHE
SCHEMBL24136591 0.80 PARP10 (0.42) PARP10PARP1F7F3ACHE
SCHEMBL30466437 0.80 PARP10 (0.42) PARP10PARP1F7F3ACHE
SCHEMBL15814001 0.78 PARP10 (0.47) PARP10PARP1F7F3ACHE
SCHEMBL14842620 0.77 ACHE (0.54) PARP10PARP1F7F3ACHE
SCHEMBL24136634 0.75 ACHE (0.43) PARP10PARP1F7F3ACHE
SCHEMBL24681239 0.75 PARP10 (0.44) PARP10PARP1F7F3ACHE
SCHEMBL22713717 0.75 PARP10 (0.44) PARP10PARP1F7F3ACHE
SCHEMBL15813912 0.75 PARP1 (0.44) PARP10PARP1F7F3ACHE
SCHEMBL15999488 0.73 PARP10 (0.42) PARP10PARP1F7F3PARP11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763539-B1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LTD (GB) 2017-02-08 — — EP disclosed
US-9340556-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2016-05-17 — — US disclosed
US-9340556-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2016-05-17 — — US disclosed
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-09-04 — — US disclosed
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-09-04 — — US disclosed
WO-2013052568-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS MRPL21, PEPD, ABCB11 PARP10 4143/4885PARP1 4430/4885F7 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback